Phase II trial to evaluate the rate of immune response using idiotype [Genitope Corporation] immunotherapies produced by molecular biological means for treatment of aggressive B-cell lymphoma
Phase of Trial: Phase II
Latest Information Update: 22 Jan 2018
At a glance
- Drugs GTOP 99; Sargramostim
- Indications Non-Hodgkin's lymphoma
- Focus Therapeutic Use
- 13 Jan 2018 Status changed from active, no longer recruiting to completed.
- 24 Sep 2005 New trial record.